Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy
about
In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studiesThe molecular biology of WHO grade I astrocytomasTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondPD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem gliomaA Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.Pediatric high-grade glioma: biologically and clinically in need of new thinkingCDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.Detection of a Distinctive Genomic Signature in Rhabdoid Glioblastoma, A Rare Disease Entity Identified by Whole Exome Sequencing and Whole Transcriptome SequencingMolecular markers in pediatric neuro-oncology.Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating CellsUnique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma.Pediatric gliomas as neurodevelopmental disordersTargeting Wee1 for the treatment of pediatric high-grade gliomas.Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma modelPediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?The evolving molecular genetics of low-grade glioma.Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.Molecular pathology of paediatric central nervous system tumours.Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation.New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model.BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea-Induced Gliomagenesis.Next generation sequencing as an aid to diagnosis and treatment of an unusual pediatric brain cancer.BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.Glioma.Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.Molecular Basis of Pediatric Brain Tumors.p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.Reconstructing the molecular life history of gliomas.The cyclin-like protein Spy1 regulates growth and division characteristics of the CD133+ population in human glioma.Lgl1 controls NG2 endocytic pathway to regulate oligodendrocyte differentiation and asymmetric cell division and gliomagenesis
P2860
Q26820289-3765FC16-FD1F-4A26-8C60-4B13FDCA1FAFQ27010414-5438B2A3-0B27-4CB0-AC1A-92D577211AF6Q27026323-C7434B55-3567-41F0-8038-0EECF3385F05Q28533981-DE1747DF-0B56-42E4-8E8A-7A0219F220BCQ33571714-017551B6-DEC4-4B96-8BE0-E18D94BD7A5CQ33777868-40559A76-8921-4C16-8621-30CE65BE447FQ34004428-D7FC2EB8-5040-4B4A-96E2-E5E4D9E899BDQ35920997-3B671BB6-D108-4C1E-868E-7FDDEBC079B4Q36038003-83C06E7F-BAA4-4BFA-BF17-835FAE87DC2EQ36344704-A7145E4F-28FD-446A-80E4-DBA48B784D93Q36421110-FCAAC2BB-FEC7-4E08-8D6B-B843A143CF66Q36561184-C615A3ED-865B-447F-BF05-714F505537EFQ36803476-4446541A-AEEA-445F-BF63-A6506CF50B9CQ37580495-64C2EE2B-1945-4628-B8A5-BD724B716558Q37689031-43B711A7-E1EC-4651-8A7C-DC788BE4ECC4Q38233425-DC09C2D0-BC54-486C-BF21-6FD5D1DCFD8CQ38349169-E9F2E269-C642-4159-BA1D-F72A3DCD2F9DQ38382607-BD938EBF-248B-4622-AB80-562A718C9767Q38905187-D32049E5-FAAF-4AFF-9217-479ACF4D129DQ38971961-77F69F9B-3B82-4446-AF03-B16F744BE052Q39291616-9E6BBB1C-E327-4A98-B527-F04A0B0FA1F1Q41493335-E1026DD3-8858-49F4-A654-A04B8B97CFB3Q41630229-39DF349C-9424-4DB6-9BEC-3D6C417DE480Q42242778-7BB0CF6A-C112-49A0-BCFC-A39F563DAD11Q42731010-905E250D-3AE1-4E77-81C8-6194772F47A0Q46122173-50ABE0AA-D55A-4EED-B75B-E2A569E39C60Q46132721-286D98DC-357B-4902-A061-3629D045DDF6Q46820292-CF2A9D85-038E-423D-BE0C-45F1D98D3460Q47447546-18FB19D9-4AFB-4A04-A681-7E0B7E8451E1Q48023007-6B332A86-046D-4DD2-B35B-9A6E018F2276Q48026380-F8C92399-2D72-4C6D-B6C9-B773459859E2Q48258617-9F2A03D5-25D7-4F39-9703-E1370CF1B173Q52608306-B9587828-F4E8-4B21-B90B-08722B0CBCC6Q53050275-580A2EC5-AEE6-4A17-BDFB-F3B8B13F0DF1Q58730941-A44203D9-842C-4978-9419-341F97760537
P2860
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cooperative interactions of BR ...... s a basis for rational therapy
@ast
Cooperative interactions of BR ...... s a basis for rational therapy
@en
type
label
Cooperative interactions of BR ...... s a basis for rational therapy
@ast
Cooperative interactions of BR ...... s a basis for rational therapy
@en
prefLabel
Cooperative interactions of BR ...... s a basis for rational therapy
@ast
Cooperative interactions of BR ...... s a basis for rational therapy
@en
P2093
P2860
P356
P1476
Cooperative interactions of BR ...... s a basis for rational therapy
@en
P2093
Amélie Griveau
Arie Perry
C David James
Claudia Petritsch
David H Rowitch
Emmanuelle Huillard
Joanna J Phillips
Martin McMahon
Rebecca A Ihrie
Rintaro Hashizume
P2860
P304
P356
10.1073/PNAS.1117255109
P407
P577
2012-05-14T00:00:00Z